Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

Completed · Phase 2

Conditions studied: Gram-Positive Bacterial Infections

In brief

The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.

Key facts

Study ID

NCT00062647

Run by

Cumberland Pharmaceuticals

People needed

60

Starts

2003-08-01

Expected to finish

2006-08-01

Last updated by the study team

2019-01-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented S. aureus bacteremia

You may not qualify if…

• Patients who had received or would have received more than 72 hours of potentially effective systemic antistaphylococcal therapy within 7 days prior to randomization. The following agents were considered potentially effective antistaphylococcal therapy: antistaphylococcal penicillins (including nafcillin, oxacillin, or cloxacillin), cephalosporins, fluoroquinolones, glycopeptides (including vancomycin and teicoplanin) and linezolid

Where it is running

• Wellstar Infectious Disease — Marietta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.